ADXN

Addex Therapeutics Ltd (NASDAQ:ADXN) is a Swiss development-stage biopharmaceutical company founded in 2002 and headquartered in Geneva. The company specializes in discovering and developing small-molecule pharmaceutical products targeting central nervous system disorders through its proprietary allosteric modulation technology platform. After going public in February 2020, Addex has evolved from a traditional biotech focused on advancing its own pipeline to a more asset-light model, having spun out its preclinical programs into Neurosterix in 2024 while retaining key partnerships and a focused development strategy.